BSL01

About Retinset

Retinset is a Spanish clinical-stage biotech spin-out from Medical Mix, focused on addressing the significant unmet need in early-stage diabetic retinopathy (DR). The company has developed a proprietary drug delivery platform that enables therapeutic agents to reach the retina via eye drops, a non-invasive alternative to current late-stage interventions. Its lead candidate, BSL01, has successfully completed a Phase I clinical trial and aims to stop and even reverse the progression of DR in its early stages. Retinset targets a global patient population of over 140 million people suffering from DR.

Therapeutic Areas